



Press release December 10, 2018

## Follicum signs agreement with Centre for Skin Sciences at University of Bradford for Mode of Action studies

**Follicum AB ("Follicum" or "Company"), a biotech company developing new peptide drugs in two areas, hair loss and diabetes, today reports that a collaboration agreement with the Centre for Skin Sciences (CSS) at University of Bradford, UK, has been signed. The aim is to combine *in vitro* experiments with the use of bioinformatics data mining and analysis to investigate the mode of action of Follicum's different peptide classes using an *in silico* approach (big data analysis). The scope of the project will cover both skin/hair biology and diabetes.**

Follicum has, as previously reported, made major progress in identifying the receptors for their peptides of interest. CSS has a unique access to human skin material and will assist Follicum in investigating the biological activity of Follicum's peptides in a collaborative way using various advanced experimental assays. The aim of the research is to achieve a better understanding of the mode of action of Follicum's peptides utilising the vast experience of CSS. A better characterization of the mode of action in both projects will help advance ongoing partner discussions.

### **CEO Jan Alenfall comments**

*"We are very pleased to have signed this agreement. The vast experience that CSS brings to the project is of great importance to increase the understanding of the mechanism of action of our peptides both in the hair and diabetes. It is important to intensify this research as we are getting closer to starting more advanced clinical trials in the hair project. The understanding will also help develop the diabetes project further. The studies will be initiated early 2019 and completed later the same year."*

### **For further information, please contact:**

Jan Alenfall – CEO, Follicum AB  
Telephone: +46 46 19 21 97  
Email: [info@follicum.com](mailto:info@follicum.com)

*This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 10<sup>th</sup> of December 2018.*

---

### **About Follicum AB**

Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicum's research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. [www.follicum.com](http://www.follicum.com).

### **About Centre for Skin Sciences (CSS), University of Bradford, Yorkshire, UK**

The Centre for Skin Sciences (CSS) is one of the largest academic centres in Britain for fundamental and translational skin and hair follicle research. The Centre's internationally renowned scientists have been integrating basic science with applied research for over 30 years, contributing to a greater understanding of what is required for healthy skin and hair. The research explores the cellular and molecular processes underlying skin and hair biology in both health and disease including world leading research focussed on the role of epigenetic processes in skin and hair biology. CSS work with industry partners to help turn this fundamental understanding into exciting opportunities for developing new technology and products. CSS work with human tissues and cells to maximise translation of the work to consumers and patients. [www.bradford.ac.uk/CSS](http://www.bradford.ac.uk/CSS)